RxDoctor Payments Data

Peter Ocarroll, MD

Neurology · Granbury, TXNPI 1811190812

Payments from drug & device makers

$137,379in general payments, 2019–2025

Across 1,363 payments — averaging $100.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96K
  • Amgen$28K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$1K
  • Biogen$1K
  • Lilly USA, LLC$863
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$115,30184%
  • Travel & lodging$2,1022%
  • Food & beverage$19,65114%
  • Education$3250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)363$95,906
Amgen(2 entities)100$27,916
Teva Pharmaceuticals USA, Inc.91$1,492
UCB, Inc.103$1,357
Biogen76$1,102
Lilly USA, LLC51$863
Supernus Pharmaceuticals, Inc.49$847
Novartis57$750
Pfizer71$621
Amneal Pharmaceuticals LLC43$577
SK Life Science, Inc.29$495
Sunovion Pharmaceuticals Inc.47$485
Eisai Inc.14$444
Neurocrine Biosciences, Inc.20$319
Lundbeck LLC18$282
Sanofi16$270
Genentech USA, Inc.16$263
MDD US Operations, LLC10$239
Neurelis, Inc.11$222
Adamas Pharmaceuticals, Inc.12$211
Upsher-smith Laboratories LLC12$191
Argenx US, Inc.10$189
Biohaven Pharmaceuticals, Inc.14$167
Biohaven Pharmaceutical Holding Company Ltd.12$166
Alnylam Pharmaceuticals Inc.8$150
Kyowa Kirin, Inc.7$144
Sumitomo Pharma America, Inc.10$126
Acadia Pharmaceuticals Inc8$115
Aucta Pharmaceuticals, Inc.8$107
TG Therapeutics, Inc.3$97
Ipsen Biopharmaceuticals, Inc4$92
AstraZeneca6$88
Otsuka America Pharmaceutical, Inc.5$87
Acorda Therapeutics, Inc6$82
Tanabe Pharma America, Inc.4$67
Avanir Pharmaceuticals, Inc.5$65
Currax Pharmaceuticals LLC4$57
Avion Pharmaceuticals3$55
EMD Serono, Inc.4$55
C2n Diagnostics, LLC2$54
Medtronic2$51
Axsome Therapeutics, Inc.2$45
Grifols USA, LLC2$37
Promius Pharma LLC3$37
Almatica Pharma LLC2$34
Abbott2$31
Impel Pharmaceuticals Inc.2$28
Takeda Pharmaceuticals U.S.A., Inc.1$27
GE HealthCare1$25
Nevro Corp.1$24
Corium, LLC1$23
CSL Behring1$23
Mallinckrodt Enterprises LLC1$22
Aquestive Therapeutics, Inc.1$18
Greenwich Biosciences, Inc.1$18
Boston Scientific1$18
Johnson & Johnson1$18
Mallinckrodt Hospital Products Inc.1$17
Impel Pharmaceuticals LLC1$15
Jazz Pharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,379 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$217,227
Medicare patients
656
Services billed
8,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine21$294,900
GammakedImmune Globul G/Gly/Iga Avg 4629$199,098
IngrezzaValbenazine Tosylate22$178,592
Austedo XrDeutetrabenazine22$177,018
VumerityDiroximel Fumarate18$150,791
BriviactBrivaracetam81$122,865
UbrelvyUbrogepant84$117,405
NuplazidPimavanserin Tartrate21$103,887
RytaryCarbidopa/Levodopa66$81,669
Emgality PenGalcanezumab-Gnlm108$79,616
Aimovig AutoinjectorErenumab-Aooe111$78,755
BotoxOnabotulinumtoxina57$77,598
QuliptaAtogepant55$76,135
GlatopaGlatiramer Acetate19$66,878
NuedextaDextromethorphan Hbr/Quinidine31$62,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,492$471,91843 claims
AbbVieUbrelvy, Botox, Qulipta$95,906$271,138196 claims
Neurocrine Biosciences, Inc.Ingrezza$319$178,59222 claims
BiogenVumerity$1,102$150,79118 claims
UCB, Inc.Briviact$1,357$122,86581 claims
Acadia Pharmaceuticals IncNuplazid$115$103,88721 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$577$90,539183 claims
Avanir Pharmaceuticals, Inc.Nuedexta$65$62,48831 claims
PfizerNurtec Odt, Eliquis$621$42,02242 claims
Otsuka America Pharmaceutical, Inc.Rexulti$87$40,35027 claims
Upsher-smith Laboratories LLCTopiramate$191$2,197221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →